Written question asked by Anna Sabine (Liberal Democrat) on Wednesday, 15 April 2026, in the House of Commons. It was due for an answer on Tuesday, 21 April 2026 (named day). A holding answer was provided on Wednesday, 22 April 2026. A substantive answer was provided by Zubir Ahmed (Labour) on Wednesday, 22 April 2026 on behalf of the Department of Health and Social Care.
Liothyronine
- Question
-
To ask the Secretary of State for Health and Social Care, what discussions he has had with Integrated Care Boards on policies on liothyronine, including requiring Exceptional/Individual Funding Requests and applying bans on new patients; and if he will issue guidance to prevent restrictions where NHS England guidance supports its use in some patients.
- Answer
-
The Department has not held any discussions with integrated care boards regarding their policies on liothyronine. NHS England regional teams have distributed the Items that should not be prescribed in primary care policy guidance to local healthcare systems. These systems are responsible for ensuring that prescribing practices follow the guidance provided.
Secondary information
- Type
- Written question
- Reference
- 127691
- Session
- 2024-26
- Grouped for answer
- Yes
- Subjects
- Liothyronine
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2026-04-22 11:02:04 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/127691
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/127691
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/127691